Previous close | 1,049.00 |
Open | 1,052.00 |
Bid | 1,067.00 x 0 |
Ask | 1,070.40 x 0 |
Day's range | 1,052.00 - 1,070.60 |
52-week range | 720.40 - 1,070.60 |
Volume | |
Avg. volume | 1,538,024 |
Market cap | 2.401T |
Beta (5Y monthly) | 0.31 |
PE ratio (TTM) | 43.09 |
EPS (TTM) | 24.76 |
Earnings date | 04 May 2023 |
Forward dividend & yield | 12.40 (1.20%) |
Ex-dividend date | 24 Mar 2023 |
1y target est | 1,016.08 |
Novo Nordisk (NVO) announces positive top-line results from its phase III increased dosage study of semaglutide, 25 mg and 50 mg, for the treatment of patients with type II diabetes.
Bagsværd, Denmark, 27 March 2023 – On 1 February 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 28 billion to be executed during a 12-month period beginning 1 February 2023. Under the programme i
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.